Skip to content

Beam Therapeutics

US · BEAM #2614 by market cap Listed 2020
20.90 -0.04 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 2.48 In line with history 34th percentile
5-year average 3.10 · #281 of 514 in Biotechnology
P/E ratio -25.94 Cheap vs history 15th percentile
5-year average -15.08 · forward -4.37
P/S ratio 16.11 Cheap vs history 21st percentile
5-year average 384.79 · forward 121.14 · #205 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Beam Therapeutics (BEAM) 2.16B -23.75 2.27 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value27.70 Economic moatNone UncertaintyHigh

Trading 32.5% below Morningstar's fair value estimate.

Fair value

Beam Therapeutics Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 18% discount to our quantitative fair value estimate of $27.70 per share; however, caution is warranted due to this estimate's high uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.

Beam Therapeutics discussion 0 comments

Add a comment